If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> VOL. 22 SUPPL. 1 A SUPPLEMENT TO www.clinicianreviews.com<br /> Optimizing Patient Outcomes in<br /> Diabetes Management<br /> ■ Individualizing Diabetes Therapy<br /> ■ Challenges of Adherence: Room<br /> for Improvement<br /> ■ Managing Hypoglycemia<br /> ■ Advances in Diabetes Therapies<br /> This supplement is<br /> supported by funding<br /> from Novo Nordisk Inc.<br /> A Supplement to<br /> www.clinicianreviews.com<br /> A Supplement to<br /> PUBLISHING<br /> Executive VP, QHI, President, Primary Care Group<br /> JoAnn Wahl<br /> (973) 206-8989<br /> E-mail: joann.wahl@qhc.com<br /> Group Publisher<br /> Christy Tetterton<br /> (973) 206-8984<br /> E-mail: christy.tetterton@qhc.com<br /> National Account Manager<br /> Steve Farrell<br /> (973) 206-2322<br /> E-mail: steve.farrell@qhc.com<br /> Senior Account Manager/Advertising Sales<br /> K<a title="CR NovoNordisk Digital Edition page 1" href="http://viewer.zmags.com/publication/fd4fd239?page=1"> VOL. 22 SUPPL. 1 </a> <a title="CR NovoNordisk Digital Edition page 2" href="http://viewer.zmags.com/publication/fd4fd239?page=2"> A Supplement to www.clinicianreviews.com</a> <a title="CR NovoNordisk Digital Edition page 3" href="http://viewer.zmags.com/publication/fd4fd239?page=3"> A Supplement to PUBLISHING Executive VP,</a> <a title="CR NovoNordisk Digital Edition page 4" href="http://viewer.zmags.com/publication/fd4fd239?page=4"> Introduction The Role of the PA/NP in Diabetes </a> <a title="CR NovoNordisk Digital Edition page 5" href="http://viewer.zmags.com/publication/fd4fd239?page=5"> need for new treatment options for management of </a> <a title="CR NovoNordisk Digital Edition page 6" href="http://viewer.zmags.com/publication/fd4fd239?page=6"> Individualizing Diabetes Therapy Scott Urquhart,</a> <a title="CR NovoNordisk Digital Edition page 7" href="http://viewer.zmags.com/publication/fd4fd239?page=7"> in A1C levels. The risk for hypo- glycemia with T</a> <a title="CR NovoNordisk Digital Edition page 8" href="http://viewer.zmags.com/publication/fd4fd239?page=8"> TABLE 2: Characteristics of Commonly Used Insulin</a> <a title="CR NovoNordisk Digital Edition page 9" href="http://viewer.zmags.com/publication/fd4fd239?page=9"> its use with insulin has been associated with an </a> <a title="CR NovoNordisk Digital Edition page 10" href="http://viewer.zmags.com/publication/fd4fd239?page=10"> A PA's Experience with Insulin: Pearls for Starti</a> <a title="CR NovoNordisk Digital Edition page 11" href="http://viewer.zmags.com/publication/fd4fd239?page=11"> level of >7% for 10 years.9 This unnecessary dela</a> <a title="CR NovoNordisk Digital Edition page 12" href="http://viewer.zmags.com/publication/fd4fd239?page=12"> Challenges of Adherence in Diabetes Care: Room fo</a> <a title="CR NovoNordisk Digital Edition page 13" href="http://viewer.zmags.com/publication/fd4fd239?page=13"> problems and that many have poor psychological we</a> <a title="CR NovoNordisk Digital Edition page 14" href="http://viewer.zmags.com/publication/fd4fd239?page=14"> </a> <a title="CR NovoNordisk Digital Edition page 15" href="http://viewer.zmags.com/publication/fd4fd239?page=15"> Case Scenario: Strategies for Changing Patient Be</a> <a title="CR NovoNordisk Digital Edition page 16" href="http://viewer.zmags.com/publication/fd4fd239?page=16"> through the stages of change and encouraged to st</a> <a title="CR NovoNordisk Digital Edition page 17" href="http://viewer.zmags.com/publication/fd4fd239?page=17"> Managing Hypoglycemia in Patients with Type 2 Dia</a> <a title="CR NovoNordisk Digital Edition page 18" href="http://viewer.zmags.com/publication/fd4fd239?page=18"> cometer readings and make adjustments based on th</a> <a title="CR NovoNordisk Digital Edition page 19" href="http://viewer.zmags.com/publication/fd4fd239?page=19"> are at higher risk for drug-associated hypoglyce-</a> <a title="CR NovoNordisk Digital Edition page 20" href="http://viewer.zmags.com/publication/fd4fd239?page=20"> derstanding will provide a sense of greater contr</a> <a title="CR NovoNordisk Digital Edition page 21" href="http://viewer.zmags.com/publication/fd4fd239?page=21"> Advances in Diabetes Therapies Jeff Unger, MD </a> <a title="CR NovoNordisk Digital Edition page 22" href="http://viewer.zmags.com/publication/fd4fd239?page=22"> receptor agonists and DPP-4 inhibitors, are effec</a> <a title="CR NovoNordisk Digital Edition page 23" href="http://viewer.zmags.com/publication/fd4fd239?page=23"> the subcutaneous tissue. The insulin com- plex bo</a> <a title="CR NovoNordisk Digital Edition page 24" href="http://viewer.zmags.com/publication/fd4fd239?page=24"> ited an 18% lower rate (P = .036) of overall conf</a> <a title="CR NovoNordisk Digital Edition page 25" href="http://viewer.zmags.com/publication/fd4fd239?page=25"> AstraZeneca) to provide additional data in regard</a> <a title="CR NovoNordisk Digital Edition page 26" href="http://viewer.zmags.com/publication/fd4fd239?page=26"> daily, and 1049 patients were given placebo. The </a> <a title="CR NovoNordisk Digital Edition page 27" href="http://viewer.zmags.com/publication/fd4fd239?page=27"> 22. Ferrannini E, Ramos SJ, Salsali A, et al. Dap</a> <a title="CR NovoNordisk Digital Edition page 28" href="http://viewer.zmags.com/publication/fd4fd239?page=28"> </a>